Allogene Therapeutics, Inc.
ALLO•NASDAQ
Allogene Therapeutics, Inc.
ALLO•NASDAQ
Mkt Cap$294.40M
Sentiment
Phase 1 · Company Overview
Step 1: Overview
What the company does, where it operates, and who runs it.
Overview for Allogene Therapeutics, Inc.
Industry:Biotechnology
Sector:Healthcare
CEO:David D. Chang
Description:Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Address:210 East Grand Avenue, South San Francisco, CA, US
Step 2: Infographics
Visual summary of the business at a glance.
Phase 2 · FRC Research
Step 3: Media
Videos and interviews covering the company.
Phase 3 · Financial Data
Step 4: Stock Data
Price chart, volume, and trading data.
ALLO Stock Price
Step 5: Fair Value
What FRC thinks the stock is worth vs. the current price.
Step 6: Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Step 7: Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Step 8: Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Step 9: Financial Statements
Income statement, balance sheet, and cash flow statements.
Phase 4 · Peer Comparison
Step 10: Comparables
List of peer companies in the same industry.
Phase 5 · Ownership & News
Step 12: Institutional Ownership
Which funds and firms own the stock.
Step 13: Insider Trading
Recent buying and selling by company executives.
Step 14: Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
Step 15: News
Latest headlines and market coverage.
News
Latest Market News